These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1301 related articles for article (PubMed ID: 31672028)

  • 1. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
    Perales IJ; San Agustin K; DeAngelo J; Campbell AM
    Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation.
    Kido K; Ngorsuraches S
    Ann Pharmacother; 2019 Feb; 53(2):165-170. PubMed ID: 30130979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients.
    Kalani C; Awudi E; Alexander T; Udeani G; Surani S
    Hosp Pract (1995); 2019 Oct; 47(4):181-185. PubMed ID: 31580732
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparing DOAC and warfarin outcomes in an obese population using the 'real-world' Michigan Anticoagulation Quality Improvement Initiative (MAQI
    Ardeshna N; Feldeisen T; Kong X; Haymart B; Kaatz S; Ali M; Barnes GD; Froehlich JB
    Vasc Med; 2024 Oct; 29(5):543-552. PubMed ID: 39177515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs.
    Spyropoulos AC; Ashton V; Chen YW; Wu B; Peterson ED
    Thromb Res; 2019 Oct; 182():159-166. PubMed ID: 31493618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
    Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP
    Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation.
    Peterson ED; Ashton V; Chen YW; Wu B; Spyropoulos AC
    Am Heart J; 2019 Jun; 212():113-119. PubMed ID: 30981035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Direct Oral Anticoagulants vs Warfarin in Patients With Obesity and Venous Thromboembolism: A Retrospective Analysis.
    Tu ZH; Perez AD; Diaz TE; Loop MS; Clarke M
    Tex Heart Inst J; 2024 May; 51(1):. PubMed ID: 38748549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Major Bleeding, Stroke/Systemic Embolism, and Death Associated With Different Oral Anticoagulants in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease.
    Xu Y; Ballew SH; Chang AR; Inker LA; Grams ME; Shin JI
    J Am Heart Assoc; 2024 Aug; 13(16):e034641. PubMed ID: 39119973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism.
    Coons JC; Albert L; Bejjani A; Iasella CJ
    Pharmacotherapy; 2020 Mar; 40(3):204-210. PubMed ID: 31968126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data.
    Costa OS; Beyer-Westendorf J; Ashton V; Milentijevic D; Moore KT; Bunz TJ; Coleman CI
    J Thromb Thrombolysis; 2021 Feb; 51(2):349-358. PubMed ID: 32588288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health Economic Analysis of Rivaroxaban and Warfarin for Venous Thromboembolism Management in Chinese Patients.
    Fung KP; Chan KH; Ng V; Tsui PT; You JHS
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):331-337. PubMed ID: 30888571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism.
    Novak AR; Shakowski C; Trujillo TC; Wright GC; Mueller SW; Kiser TH
    J Thromb Thrombolysis; 2022 Aug; 54(2):276-286. PubMed ID: 35689140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism.
    Kohn CG; Bunz TJ; Beyer-Westendorf J; Coleman CI
    Eur J Haematol; 2019 Feb; 102(2):143-149. PubMed ID: 30328143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial).
    Balla SR; Cyr DD; Lokhnygina Y; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Singer DE; Patel MR
    Am J Cardiol; 2017 Jun; 119(12):1989-1996. PubMed ID: 28477860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor Xa Inhibitors versus warfarin in patients with morbid obesity and atrial fibrillation.
    Dobry P; McGrew K; Yun I; Heath R; Shafqat A; Ascend-Higher ; Giuliano C
    Eur J Clin Pharmacol; 2024 Jul; 80(7):1039-1050. PubMed ID: 38507060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing the Clinical Outcomes Observed with Rivaroxaban Versus Warfarin for the Management of Obese Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis.
    Zhuo X; Wang J; Shao L
    Cardiovasc Drugs Ther; 2024 Feb; 38(1):79-89. PubMed ID: 35763193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study.
    Signorelli JR; Gandhi AS
    J Oncol Pharm Pract; 2019 Mar; 25(2):362-368. PubMed ID: 29157146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.